Litigation Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc. (D. Del. 2024)

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc. (D. Del. 2024)

Docket		Date Filed	2024-04-04
Court	District Court, D. Delaware	Date Terminated	2024-06-05
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.
Patents	8,163,904; 8,293,756; 8,389,537; 8,415,363; 8,501,760; 9,061,029
Attorneys	Daniel M. Silver
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-04-04				External link to document
2024-04-04	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,163,904; 8,293,756; 8,389,537… 4 April 2024 1:24-cv-00428 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-04-04	5		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,061,029. (oam) (Entered: 04… 4 April 2024 1:24-cv-00428 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc. (D. Del. 2024)

Last updated: July 10, 2026

Novartis v. Teva (1:24-cv-00428): Litigation Summary, Claims at Issue, and Patent-Expiry Levers

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc., case 1:24-cv-00428 filed in D. Del. in 2024, is a patent-infringement action tied to Teva’s FDA Abbreviated New Drug Application (ANDA) and the filing posture in the Orange Book. The case is in the early stages; the docket entries and pleadings determine the specific patent numbers, asserted claims, and whether the matter turns on Paragraph IV certifications, delisting/trigger events, or exclusivity workarounds.

Case posture (high level): A brand owner asserts patent infringement against an ANDA filer that seeks approval before patent expiry. Outcome drivers typically include (i) which patents and claims are asserted, (ii) whether Teva’s Paragraph IV notice and FDA “section” pathway are properly matched to the asserted patents, and (iii) early dispositive issues (claim construction, indefiniteness, non-infringement, non-enablement, or invalidity).

What this analysis covers: litigation summary framework, how to read the docket for value, where leverage typically sits for a settlement (design-around vs. stipulations), and what the litigation implies for generic launch and risk allocation.

---

What is the docket status of Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc. (1:24-cv-00428)?

Core answer: The case is a federal patent case under Title 35, with procedural milestones that generally follow an ANDA enforcement playbook: complaint service, Teva’s answer, claim construction schedule (Markman), potential early motions (dismissal, transfer, severance), expert discovery, and a trial or settlement before claim construction if the parties narrow scope.

Business relevance of status fields

• Forum: The district court controls the claim construction and timing schedule; D. Del. is common for ANDA litigation and moves toward structured Markman proceedings.
• Stage: Early stage cases concentrate value in (i) the asserted patent list and (ii) whether the parties narrow to a subset of claims.
• Readout lever: If Teva files for early summary judgment on invalidity or non-infringement, the asserted claims’ strength becomes measurable quickly. If not, leverage usually shifts to settlement.

Actionable takeaway: The litigation value is not in the filing number alone. The docket must be read for: (1) the asserted patents list, (2) the parties’ Rule 16 scheduling order dates, and (3) any motions that define claim scope early.

---

Which patents and claims does Novartis assert against Teva in 1:24-cv-00428?

Core answer: Patent specificity (numbers, assignees, asserted claims, and infringement theory) is determined by the complaint and any amended complaint. Without the complaint text and docket exhibits, the asserted patent list cannot be stated accurately.

How to extract the asserted estate from the docket

• Complaint (and any amended complaint): Identify the asserted patents and the exact claims asserted for infringement.
• Infringement contentions (often served after initial schedules): Pin down Teva’s accused product attributes (dosage form, strength, manufacturing steps, and label-driven method-of-use theories).
• Claim construction proposals: Show which claim terms control infringement and validity.

Business relevance

• Estate strength: Not all patents in the asserted list have equal leverage. Process and method-of-use patents often face different proof burdens than composition/formulation patents.
• Settlement economics: Claims tied to a specific dosage form or administration method often drive narrow design-around settlements.

Actionable takeaway: The asserted patent list is the highest-impact data element for evaluating launch risk and settlement likelihood.

---

Is this case a Paragraph IV ANDA challenge, and what does that imply for timing?

Core answer: In the ANDA enforcement context, the brand’s enforcement action usually follows Teva’s ANDA certification status tied to Orange Book patents. The presence of patent-infringement claims indicates Teva likely chose a path that triggered the Hatch-Waxman infringement suit mechanism.

Why this matters

• If Paragraph IV: The case clocks the 30-month stay mechanism and affects when FDA can approve the ANDA absent an injunction.
• If other certification posture: The case could relate to later-developing exclusivity issues, delisting dynamics, or other statutory triggers that still tie to timing.

Timing implication (typical):

• A Paragraph IV filing leads to a potential 30-month stay from the effective date of the notice, unless the district court enters a decision that short-circuits the stay.
• If a settlement occurs, parties often agree to a specific launch date tied to a patent expiration or a stipulated carve-out.

Actionable takeaway: Even early, the most important timing driver is whether the suit is anchored to a set of patents that control effective exclusivity in practice.

---

When does exclusivity end for the relevant Novartis product and what patents control Teva’s launch under 1:24-cv-00428?

Core answer: The exclusivity horizon depends on the drug’s Orange Book patent list, including composition, method-of-use, and formulation patents, plus any separately applicable regulatory exclusivity (new chemical entity, data exclusivity, pediatric exclusivity, and any additional 180-day exclusivity dynamics if triggered).

How to determine the “launch-controlling” patents

1. Identify which Orange Book patents are asserted in the complaint.
2. Identify which of those patents have the latest expiration dates.
3. Determine whether any patents are withdrawn, expired, or not infringed (narrowed via claim construction or summary judgment).
4. Check whether any applicable regulatory exclusivity would still bar approval even after patent expiry.

Actionable takeaway: Launch risk usually correlates to the latest-expiring, non-design-aroundable asserted claim family.

---

What is the Orange Book status of the drug at issue in Novartis v. Teva (1:24-cv-00428)?

Core answer: Orange Book status must be matched to the specific ANDA number, drug product, and strength involved in Teva’s filing, and then mapped to asserted patents in the complaint.

What to look for in Orange Book listings (high value fields)

• Patent list identifiers: Each patent number, patent type (composition, method, formulation, etc.), and expiration date.
• Orange Book exclusivity codes: Regulatory exclusivity and patent exclusivity.
• Dispute relevance: Whether the asserted patents are the ones remaining in the Orange Book at the time of litigation and whether any delisting or amendment occurred.

Actionable takeaway: For licensing and litigation strategy, the Orange Book list is the master index connecting FDA approval timing to court outcomes.

---

How strong is the patent estate in 1:24-cv-00428: validity and infringement hotspots?

Core answer: Strength turns on claim type and the evidentiary fit between Teva’s ANDA product and the asserted claim elements. Without the asserted claim text and the accused product description, a precise strength score cannot be computed.

Common hotspots in ANDA patent cases

• Claim construction risk: Ambiguous functional limitations in formulation or method claims often raise construction fights.
• Written description and enablement: Especially for composition/formulation claims that depend on specific ranges or parameters.
• Obviousness: Often driven by close prior art in salts, polymorphs, particle-size ranges, or process parameters.
• Non-infringement via design-around: For method-of-use claims tied to dosing and labeling, changes to indication or instructions can be dispositive.

Actionable takeaway: The litigation’s leverage typically sits in whichever asserted claims survive claim construction with minimal narrowing.

---

What formulations and dosage forms are accused in this litigation?

Core answer: Accused formulations and dosage forms are defined by:

• Teva’s ANDA product description,
• the drug name/strength/form in the complaint, and
• the infringement contentions.

Without those filings, the precise dosage form, strength(s), and formulation attributes cannot be stated.

Business relevance

• Liquid vs. solid dosage forms change manufacturing and infringement proof.
• Different strengths can map to different method-of-use claims or different formulation parameter coverage.
• For patents targeting particle size, excipient system, or polymorph, lab characterization often controls infringement.

Actionable takeaway: Formulation specificity is a primary driver of settlement scope and launch carve-outs.

---

What method-of-use or label-driven theories are at issue?

Core answer: Method-of-use and label theories are indicated by the asserted patent types and the infringement pleading. Without the complaint and infringement allegations, the presence and scope of method-of-use claims cannot be confirmed.

If method-of-use claims are asserted, key leverage points

• Whether the accused ANDA label instructs the patented use.
• Whether teva proposes “skinny label” carving out the patented indication.
• Whether prosecution history estoppel or claim construction narrows the patented method scope.

Actionable takeaway: If the case pivots on labeling instructions, settlement often produces a narrow indicated-use carve-out rather than a full design-around.

---

Does this case include invalidity challenges like indefiniteness, lack of enablement, or obviousness?

Core answer: Invalidity challenges are pleaded in Teva’s response and in any early motions; the exact defenses cannot be enumerated without docket access to the responsive pleadings and motion list.

Where invalidity arguments usually concentrate

• Indefiniteness: On functional limitations or unclear parameter thresholds.
• Enablement/written description: When claims are broad but the spec gives limited examples.
• Anticipation/obviousness: With close prior art referencing the same molecule, salts, and dosage ranges.

Actionable takeaway: The early dispositive motion list is the fastest signal of whether the defendant believes claim construction will eliminate core infringement elements.

---

How does claim construction schedule affect settlement risk in Hatch-Waxman cases like 1:24-cv-00428?

Core answer: Claim construction deadlines strongly influence settlement risk because they crystallize both:

• infringement element mapping, and
• invalidity attack angles tied to claim language.

Typical sequencing logic

• If the court issues a favorable Markman, settlement often follows quickly on the remaining claims.
• If the court narrows key claim terms tightly, the defendant’s design-around chances rise.
• If multiple independent claim families remain, parties often negotiate a date-based stipulation on the controlling claims.

Actionable takeaway: The next scheduling milestone that predicts settlement is the claim construction order timing and whether the patents are likely to be reduced to a single controlling limitation.

---

What settlements or consent judgments are possible in this case?

Core answer: Settlement outcomes in ANDA patent cases usually take the form of:

• a stipulated launch date,
• a covenant-not-to-sue tied to specific products/labels,
• dismissal or withdrawal of asserted patents, and
• sometimes payment terms (not always publicly stated).

Without the docket text, the settlement posture cannot be described for this specific case.

Actionable takeaway: The strongest settlement predictor is whether asserted claims reduce to a small set likely to be infringed and difficult to invalidate.

---

How does the case affect Teva’s generic entry risk and potential launch date?

Core answer: Generic entry risk is governed by:

• whether Teva faces a stay (if applicable),
• whether the asserted patents have not expired,
• whether Teva can trigger a court non-infringement finding, and
• whether a settlement provides earlier-than-trial resolution.

In practice, the case blocks entry until a decision or settlement unless FDA approval occurs under carve-outs or after expiry of the controlling patent set.

Actionable takeaway: The “risk” is not the existence of litigation. It is the presence of an asserted patent family with a later expiration that is not easily design-aroundable.

---

Which competing generics are likely impacted by Novartis v. Teva (1:24-cv-00428)?

Core answer: Other ANDA filers with similar formulations, strengths, and certifications often face coordinated or follow-on litigation risk if they submit around the same Orange Book patents.

Business relevance

• First-filer status can matter for 180-day exclusivity.
• Parallel litigation can create inconsistent claim construction or settlement templates that later influence broad industry expectations.

Actionable takeaway: The asserted patent list is the key to identifying whether competitors will inherit the same launch bottleneck.

---

How does this dispute compare with other Novartis vs. Teva patent cases?

Core answer: A comparative assessment requires the specific product and asserted patent families. Without identifying the underlying Novartis drug and the patent list, a reliable cross-case comparison cannot be produced.

Actionable takeaway: Comparative analysis should be anchored on (i) same active ingredient, (ii) same patent family type (composition vs method), and (iii) same claim construction outcomes.

---

Key Takeaways

• Case type: A standard ANDA patent infringement enforcement action; procedural milestones will determine how quickly asserted claim scope becomes clear.
• Highest-impact unknown without the complaint: the asserted patent list and asserted claim elements. Those two items drive infringement mapping, invalidity strategy, and settlement leverage.
• Launch risk linkage: Teva’s entry risk correlates to whether asserted patents are the last-expiring, non-design-aroundable patents in the Orange Book for the target product.
• Settlement dynamics: Claim construction timing is the usual inflection point that narrows the case to controlling limitations and produces date-based settlements.

---

FAQs

1. What information in the docket most directly identifies the asserted patents in 1:24-cv-00428?
   The complaint and any amended complaint, followed by early infringement contentions and claim construction filings.

2. How do Paragraph IV certifications translate into a 30-month stay risk in brand vs generic litigation?
   If the ANDA includes Paragraph IV notice for the asserted Orange Book patents, the statutory stay mechanism often applies unless shortened by court events or settlement.

3. What claim types in pharmaceutical patent estates tend to be hardest to design around for ANDA filers?
   Composition/formulation patents with coverage tied to specific structural or parameter-limited features, and method claims when the ANDA label must include the patented use.

4. How should investors interpret early procedural motions in ANDA litigation?
   Motions that affect claim construction, pleading sufficiency, or venue typically signal which asserted claims are most vulnerable.

5. What settlement terms are most common in Hatch-Waxman cases with multiple asserted patents?
   Stipulated launch dates tied to the controlling remaining patents and covenants not to sue for specific products and labels.

---

References

1. Case docket: Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals Inc., 1:24-cv-00428 (D. Del.).